ArticleThe Journal of biological chemistry2012
Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer.
Article in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 84 citations in OpenAlex.
- Seminal Fluid Biomarkers for Early Cancer Detection: A Systematic Review.Biomedicines · 2026Review
- Calumenin, A Calcium-Binding Modulatory Protein, Effective in Pathological Calcifications and Cancers, With Therapeutic Application Promise.FASEB bioAdvances · 2025Review
- Methods for Mitochondrial DNA Damage and Depletion in Immortalized Trabecular Meshwork Cells.International journal of molecular sciences · 2025Article
- Mechanistic insights into PROS1 inhibition of bladder cancer progression and angiogenesis via the AKT/GSK3β/β-catenin pathway.Scientific reports · 2025Article
- Regulation of Molecular Biomarkers Associated with the Progression of Prostate Cancer.International journal of molecular sciences · 2024Review
- Identification of ferroptosis related genes and pathways in prostate cancer cells under erastin exposure.BMC urology · 2024Article
- CYB561 supports the neuroendocrine phenotype in castration-resistant prostate cancer.PloS one · 2024Article
- Redefining serological diagnostics with immunoaffinity proteomics.Clinical proteomics · 2023Review
- New insights into vitamin K biology with relevance to cancer.Trends in molecular medicine · 2022Review
- MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.The Journal of clinical investigation · 2022Article
- PROS1 shapes the immune-suppressive tumor microenvironment and predicts poor prognosis in glioma.Frontiers in immunology · 2022Article
- Effects of orlistat combined with enzalutamide and castration through inhibition of fatty acid synthase in a PC3 tumor-bearing mouse model.Bioscience reports · 2021Article
- Hippophae rhamnoides mediate gene expression profiles against keratinocytes infection of Staphylococcus aureus.Molecular biology reports · 2021Article
- Effects of zinc finger protein 403 on the proliferation, migration and invasion abilities of prostate cancer cells.Oncology reports · 2020Article
- Article
- Multi-omics Biomarker Pipeline Reveals Elevated Levels of Protein-glutamine Gamma-glutamyltransferase 4 in Seminal Plasma of Prostate Cancer Patients.Molecular & cellular proteomics : MCP · 2019Article
- Review
- TYRO3: A potential therapeutic target in cancer.Experimental biology and medicine (Maywood, N.J.) · 2019Review
- Article
- Hierarchical HotNet: identifying hierarchies of altered subnetworks.Bioinformatics (Oxford, England) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
Androgen deprivation constitutes the principal therapy for advanced and metastatic prostate cancers. However, this therapeutic intervention usually results in the transition to a more aggressive androgen-independent prostate cancer. The elucidation of molecular alterations during the progression to androgen independence is an integral step toward discovering more effective targeted therapies. With respect to identifying crucial mediators of this transition, we compared the proteomes of androgen-independent (PC3, DU145, PPC1, LNCaP-SF, and 22Rv1) and androgen-dependent (LNCaP and VCaP) and/or normal prostate epithelial (RWPE) cell lines using mass spectrometry. We identified more than 100 proteins that were differentially secreted in the androgen-independent cell lines. Of these, Protein S (PROS1) was elevated in the secretomes of all of the androgen-independent prostate cancer cell lines, with no detectable secretion in normal and androgen-dependent cell lines. Using quantitative PCR, we observed significantly higher (p < 0.05) tissue expression levels of PROS1 in prostate cancer samples, further indicating its importance in prostate cancer progression. Similarly, immunohistochemistry analysis revealed elevation of PROS1 in high grade prostate cancer (Gleason grade ≥ 8), and further elevation in castration-resistant metastatic prostate cancer lesions. We also observed its significant (p < 0.05) elevation in high grade prostate cancer seminal plasma samples. Taken together, these results show that PROS1 is elevated in high grade and castration-resistant prostate cancer and could serve as a potential biomarker of aggressive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.